^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

1236 - Preclinical characterization of LY3484356, a novel, potent and orally bioavailable selective estrogen receptor degrader (SERD)

Published date:
03/10/2021
Excerpt:
LY3484356 is also a potent inhibitor of ERα-mediated transcription in vitro and in vivo. It inhibits cell proliferation in wild type ERα and ESR1 Y537N mutant breast cancer cell lines. LY3484356 has demonstrated sustained and prolonged target inhibition (>75% inhibition of PGR transcription up to 96h after last dose) in...ESR1 Y537S mutant (ST941/C) xenograft tumors.